Search research articles
Contact Us
Filters
Showing results (201-210 of 264) with videos related to
Page
of 27
Sort By:
Haematologica
|
December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
Jorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Blood Advances
|
September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Blood Neoplasia
|
September 8, 2025
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Mrinal M Patnaik, Haris Ali, Eunice S Wang, et al.
Leukemia
|
January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia
|
September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Communications Biology
|
July 2, 2026
Choline-dependent methionine metabolism supports leukemia progression
Nirmalya Saha, Lauren Lachowski, Franchesca Franzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
Ruben A Mesa, Jason Gotlib, Vikas Gupta, et al.
American Journal of Hematology
|
September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Hagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 264) with videos related to
Sort By:
Page
of 27
Haematologica
|
December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
Jorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Blood Advances
|
September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Blood Neoplasia
|
September 8, 2025
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Mrinal M Patnaik, Haris Ali, Eunice S Wang, et al.
Leukemia
|
January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia
|
September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Communications Biology
|
July 2, 2026
Choline-dependent methionine metabolism supports leukemia progression
Nirmalya Saha, Lauren Lachowski, Franchesca Franzen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
Ruben A Mesa, Jason Gotlib, Vikas Gupta, et al.
American Journal of Hematology
|
September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Hagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Page
of 27